Quantbot Technologies LP Sells 7,219 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Quantbot Technologies LP lowered its position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 35.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,024 shares of the company’s stock after selling 7,219 shares during the period. Quantbot Technologies LP’s holdings in Zevra Therapeutics were worth $109,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Intech Investment Management LLC bought a new position in shares of Zevra Therapeutics during the 3rd quarter worth approximately $95,000. Charles Schwab Investment Management Inc. increased its position in shares of Zevra Therapeutics by 10.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 121,356 shares of the company’s stock valued at $842,000 after acquiring an additional 11,038 shares during the last quarter. FMR LLC lifted its holdings in Zevra Therapeutics by 282,687.5% during the third quarter. FMR LLC now owns 2,313,202 shares of the company’s stock worth $16,054,000 after acquiring an additional 2,312,384 shares during the period. MetLife Investment Management LLC boosted its position in Zevra Therapeutics by 8.1% in the third quarter. MetLife Investment Management LLC now owns 22,866 shares of the company’s stock worth $159,000 after purchasing an additional 1,717 shares during the last quarter. Finally, State Street Corp grew its stake in Zevra Therapeutics by 7.4% in the 3rd quarter. State Street Corp now owns 772,825 shares of the company’s stock valued at $5,363,000 after purchasing an additional 52,966 shares during the period. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

Zevra Therapeutics Trading Down 4.6 %

Shares of ZVRA stock opened at $7.49 on Tuesday. The stock has a market capitalization of $405.33 million, a price-to-earnings ratio of -3.80 and a beta of 1.98. The company’s fifty day simple moving average is $7.89 and its two-hundred day simple moving average is $8.21. Zevra Therapeutics, Inc. has a 1 year low of $4.20 and a 1 year high of $9.76. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings data on Tuesday, March 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.28). Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The company had revenue of $12.00 million for the quarter, compared to the consensus estimate of $8.93 million. As a group, analysts anticipate that Zevra Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on ZVRA shares. Canaccord Genuity Group lifted their target price on Zevra Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, March 13th. Guggenheim boosted their target price on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the company a “buy” rating in a research note on Thursday, March 13th. JMP Securities set a $18.00 price target on shares of Zevra Therapeutics in a research note on Wednesday, March 12th. Citigroup reiterated an “outperform” rating on shares of Zevra Therapeutics in a research note on Wednesday, March 12th. Finally, HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Zevra Therapeutics in a research report on Thursday, March 13th. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $22.29.

Insider Transactions at Zevra Therapeutics

In other Zevra Therapeutics news, CFO R. Laduane Clifton sold 11,000 shares of the company’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $7.86, for a total value of $86,460.00. Following the transaction, the chief financial officer now directly owns 51,361 shares in the company, valued at $403,697.46. This represents a 17.64 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director John B. Bode purchased 10,000 shares of the stock in a transaction on Wednesday, March 19th. The stock was acquired at an average cost of $7.96 per share, for a total transaction of $79,600.00. Following the acquisition, the director now owns 40,000 shares in the company, valued at approximately $318,400. This represents a 33.33 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders have sold 85,773 shares of company stock valued at $674,176. 2.40% of the stock is currently owned by corporate insiders.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.